A
Artica Therapeutics
Development of covalent small molecules to transform the treatment of autoimmune and inflammatory disorders
About Artica Therapeutics
Artica Therapeutics is a pioneering startup focused on developing innovative treatments for neurological disorders. The company operates in the biopharmaceutical industry, specifically targeting conditions that affect the nervous system. Artica Therapeutics serves a diverse range of clients, including patients suffering from neurological diseases, healthcare providers, and research institutions.
The market Artica Therapeutics operates in is highly specialized and competitive, with a growing demand for effective treatments for neurological conditions such as Alzheimer's, Parkinson's, and multiple sclerosis. The company leverages cutting-edge research and development (R&D) to create novel therapies that address unmet medical needs in this field.
Artica Therapeutics' business model revolves around the discovery, development, and commercialization of its proprietary drug candidates. The company invests heavily in R&D to advance its pipeline of therapeutic products through various stages of clinical trials. Once a drug candidate demonstrates efficacy and safety, Artica seeks regulatory approval to bring the product to market.
Revenue generation for Artica Therapeutics primarily comes from the successful commercialization of its drugs. This includes direct sales to healthcare providers and institutions, as well as potential licensing agreements with larger pharmaceutical companies. Additionally, the company may receive funding through grants, partnerships, and collaborations with other entities in the biopharmaceutical sector.
In summary, Artica Therapeutics is dedicated to improving the lives of patients with neurological disorders through innovative drug development. The company's focus on R&D, coupled with its strategic business model, positions it as a key player in the biopharmaceutical industry.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Nov 2023 | $13M | $53M | Thuja Capital · BioGeneration Ventures · InnovationQuarter Capital · Seroba Life Sciences | ↗ |
Growth signals
Latest recorded traffic for Artica Therapeutics is 3.2K monthly website visits, up 223.2% over the last three months. Artica Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Artica Therapeutics in the Leiden ecosystem
The Artica Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Thuja Capital
Seroba Life Sciences
BioGeneration Ventures
InnovationQuarter Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Artica Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Artica Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








